Merge pull request 'extract: 2025-12-23-jama-cardiology-select-hospitalization-analysis' (#1046) from extract/2025-12-23-jama-cardiology-select-hospitalization-analysis into main

domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md

@@ -30,6 +30,12 @@ For value-based care models and capitated payers, this multi-organ protection cr
 - Nature Medicine: additive benefits with SGLT2 inhibitors
 - First GLP-1 to receive FDA indication for CKD in T2D patients
 
+
+### Additional Evidence (extend)
+*Source: [[2025-12-23-jama-cardiology-select-hospitalization-analysis]] | Added: 2026-03-16*
+
+SELECT trial exploratory analysis (N=17,604, median 41.8 months) shows semaglutide reduces ALL-CAUSE hospitalizations by 10% (18.3 vs 20.4 per 100 patient-years, P<.001) and total hospital days by 11% (157.2 vs 176.2 days per 100 patient-years, P=.01). Critically, benefits extended beyond cardiovascular causes to total hospitalization burden, suggesting systemic effects across multiple organ systems.
+
 ---
 
 Relevant Notes:

inbox/archive/2025-12-23-jama-cardiology-select-hospitalization-analysis.md

@@ -7,9 +7,13 @@ date: 2025-12-23
 domain: health
 secondary_domains: [internet-finance]
 format: paper
-status: unprocessed
+status: enrichment
 priority: high
 tags: [glp-1, semaglutide, hospitalization, cardiovascular, SELECT-trial, cost-offset]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -36,3 +40,12 @@ Median age 61.0 years; 27.7% female; median BMI 32.1.
 PRIMARY CONNECTION: [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness]]
 WHY ARCHIVED: All-cause hospitalization reduction is the most economically relevant outcome for risk-bearing payers and the strongest evidence that GLP-1s could be cost-saving under capitation
 EXTRACTION HINT: Focus on the all-cause hospitalization signal (not just CV) — this is what makes GLP-1s relevant to VBC economics beyond cardiology
+
+
+## Key Facts
+- SELECT trial: N=17,604 patients with obesity and established CVD, median follow-up 41.8 months
+- Median age 61.0 years, 27.7% female, median BMI 32.1
+- Total hospitalizations: 18.3 vs 20.4 per 100 patient-years (mean ratio 0.90, P<.001)
+- Hospitalizations for serious adverse events: 15.2 vs 17.1 per 100 patient-years (mean ratio 0.89, P<.001)
+- Days hospitalized: 157.2 vs 176.2 per 100 patient-years (rate ratio 0.89, P=.01)
+- Published in JAMA Cardiology as prespecified exploratory analysis